Comparing SG&A Expenses: GSK plc vs Alkermes plc Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of GSK plc and Alkermes plc from 2014 to 2023.

GSK plc: A Steady Giant

GSK plc, a leader in the pharmaceutical sector, consistently allocated a significant portion of its budget to SG&A expenses. Over the decade, GSK's expenses fluctuated around the $10 billion mark, peaking in 2019 and 2020. This strategic investment underscores GSK's commitment to maintaining its market position and expanding its global reach.

Alkermes plc: A Rising Contender

In contrast, Alkermes plc demonstrated a remarkable growth trajectory, with SG&A expenses increasing by over 240% from 2014 to 2023. This surge reflects Alkermes' aggressive expansion and investment in marketing and administrative capabilities, positioning itself as a formidable player in the industry.